SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

Search

Fagron

Fermé

SecteurSoins de santé

19.26 0.52

Résumé

Variation du prix de l'action

24h

Actuel

Min

18.86

Max

19.3

Chiffres clés

By Trading Economics

Revenu

-298K

40M

Ventes

13M

443M

P/E

Moyenne du Secteur

17.346

63.778

Rendement du dividende

1.58

Marge bénéficiaire

9.066

Employés

3,828

EBITDA

-4.3M

71M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+20.59% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.58%

2.39%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

19M

1.4B

Ouverture précédente

18.74

Clôture précédente

19.26

Fagron Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 avr. 2025, 23:04 UTC

Actualités

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 avr. 2025, 22:40 UTC

Principaux Mouvements du Marché

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 avr. 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 avr. 2025, 18:51 UTC

Acquisitions, Fusions, Rachats

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 avr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 avr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 avr. 2025, 22:22 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 22:21 UTC

Acquisitions, Fusions, Rachats

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 avr. 2025, 21:43 UTC

Actualités
Résultats

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 avr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 avr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 avr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 avr. 2025, 20:34 UTC

Actualités

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 avr. 2025, 20:23 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 20:15 UTC

Acquisitions, Fusions, Rachats

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 avr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 avr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 avr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 avr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 avr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 avr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 avr. 2025, 18:38 UTC

Actualités

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 avr. 2025, 18:30 UTC

Actualités

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 avr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 avr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 avr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 avr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 avr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparaison

Variation de prix

Fagron prévision

Objectif de Prix

By TipRanks

20.59% hausse

Prévisions sur 12 Mois

Moyen 19.5 EUR  20.59%

Haut 19.5 EUR

Bas 19.5 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.